'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas

Coronary Artery Disease

Volumn 18, Issue 6, 2007, Pages 455-462

  Bilinska, Maria ^a   Potocka, Joanna ^a   Korzeniowska Kubacka, Iwona ^a   Piotrowicz, Ryszard ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Coronary artery disease; Diabetes mellitus; Exercise testing; Ischaemic preconditioning; Sulfonylureas

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DIET THERAPY; EXERCISE TEST; HEART RATE; HUMAN; ISCHEMIC PRECONDITIONING; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE;

ANGINA PECTORIS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; EXERCISE; GLICLAZIDE; GLYBURIDE; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 34547911019     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3282a30676     Document Type: Article

References (36)

1. Sumeray MS, Yellon DM. Myocardial preconditioning. What have we learned? Eur Heart J 1997; 18 (Suppl. A):A8-A14.
2. Yellon DM, Baxter GF, Garcia-Dorado D, Heusch G, Sumeray MS. Ischaemic preconditioning: present position and future directions. Cardiovasc Res 1998; 37:21-33.
3. Jenkins DP, Steare SE, Yellon DM. Preconditioning the human myocardium: recent advances and aspirations for the development of a new means of cardioprotection in clinical practice. Cardiovasc Drugs Ther 1995; 9:739-747.
4. Tomai F, Crea F, Danesi A, Perino M, Gaspardone A, Ghini A, et al. Mechanisms of the warm-up phenomenon. Eur Heart J 1996; 17:1022-1027.
5. Baxter GF. Coronary angioplasty as a model of ischaemic preconditioning: fact or fancy? Eur Heart J 1996; 17:812-814.
6. Ghosh S, Standen NB, Galinanes M. Preconditioning the human myocardium by simulated ischemia: studies on the early and delayed protection. Cardiovasc Res 2000; 45:339-350.
7. Tomai F, Crea F, Chiariello L, Gioffre PA. Ischemic preconditioning in humans. Models, mediators, and clinical relevance. Circulation 1999; 100:559-563.
8. ATP channel. Ann Rev Physiol 2000; 62:79-109.
9. Cleveland JC, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: two paradoxes revisited. Circulation 1997; 96:29-32.
10. ATP channel blockade by glibenclamide on the warm-up phenomenon. Eur Heart J 1999; 20:196-202.
11. Sato J, Ohsawa I, Oshida Y, Fukuharu M, Hu XC, Tamagawa T, et al. Comparison of the effects of three sulfonylureas on in vivo insulin action. Arzneim Forsch/Drug Res 2001; 51:459-464.
12. Maczewski M, Beresewicz A. The role of adenosine and ATP-sensitive potassium channels in the protection afforded by ischemic preconditioning against the post-ischemic endothelial dysfunction in guinea-pig hearts. J Mol Cell Cardiol 1998; 30:1735-1747.
13. Nieszner E, Posa I, Kocsis E, Pogatsa G, Preda I, Koltai MZ. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits. Exp Clin Endocrinol Diabetes 2002; 110:212-218.
14. Schulz R, Gres P, Heusch G. Activation of ATP-dependent potassium channels is a trigger but not a mediator of ischaemic preconditioning in pigs. Br J Pharmacol 2003; 139:65-72.
15. + blocker. Circulation 1994; 90:700-705.
16. Ovunc K. Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris. Clin Cardiol 2000; 23:535-539.
17. ATP channel blocker, on the warm-up phenomenon. A.N.E. 2005; 10:356-362.
18. Fisman EZ, Tenenbaum A, Motro M, Adler Y. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint. Herz 2004; 29:290-298.
19. Meier JJ, Gallwitz B, Schmidt WE, Mugge A, Nauck MA. Is impairment of ischemic preconditioning by sulfonylurea drugs clinically important? Heart 2004; 90:9-12.
20. Vegh A, Papp JG. Haemodynamic and other effects of sulphonylurea drugs on the heart. Diabetes Res Clin Practice 1996; S31:S43-S53.
21. Bijlstra PJ, den Arend JA, Lutterman JA, Russel FG, Thien T, Smits P. Blockade of vascular ATP-sensitive channels reduces the vasodilator response to ischemia in humans. Diabetologia 1996; 39:1562-1568.
22. Bank AJ, Sih R, Mullen K, Osayamwen M, Lee PC. Vascular ATP-dependent potassium channels, nitric oxide, and forearm reactive hyperemia. Cardiovasc Drugs Ther 2000; 14:23-29.
23. Jennings PE, Belch JJ. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effects of gliclazide. Metabolism 2000; 49:23-26.
24. Fuzukawa M, Satoh J, Qiang X, Miyaguchi S, Sakata Y, Nakazawa T, et al. Inhibition of tumor necrosis factor-alfa with anti-diabetic agents. Diabetes Res Clin 1999; 43:147-154.
25. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004; 18:113-119.
26. Sato T, Nishida H, Miyazaki M, Nakaya H. Effects of sulfonylureas on mitochondrial ATP-sensitive K(+) channels in cardiac myocytes: implications for sulfonylurea controversy. Diabetes Metab Res Rev 2006; 22:341-347.
27. Loubani M, Fowler A, Standen NB, Galinanes M. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol 2005; 51:142-149.
28. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103:3111-3116.
29. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, et al. Sulfonylurea and ischaemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20:439-446.
30. Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complications 2000; 14:192-196.
31. Park EJ, Bae JH, Kim SY, Lim JG, Baek WK, Kwon TK, et al. Inhibition of ATP-sensitive K + channels by taurine through a benazamido-binding site on sulfonylurea receptor 1. Biochem Pharmacol 2004; 67:1089-1096.
32. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart. The importance of Akt phosphorylation. Diabetes 2005; 54:2360-2364.
33. Tosaki A, Engelman DT, Engelman RM, Das DK. The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res 1996; 31:526-536.
34. Kloner RA, Speakman MT, Przyklenk K. Ischemic preconditioning: a plea for rationally targeted clinical trials. Cardiovasc Res 2002; 55:526-533.
35. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment an risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
36. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 322:15-18.